Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048425 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00048425 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 600 participants.
The verdict
NCT00048425, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
Interventions
- DRUG Levosimendan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2002-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048425
The ClinicalTrials.gov registry entry for NCT00048425 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levosimendan is the first listed.
NCT00048425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048425 about?
NCT00048425 is a clinical study titled "Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.". The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
What is the current status of trial NCT00048425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2002-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00048425?
The interventions under investigation include: Levosimendan (DRUG).
Who is sponsoring clinical trial NCT00048425?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.